Flagship push in diabetes care: Torrent Pharma’s Chqornet tablet under the spotlight

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 7:44 PM ET. Details in the imprint.

Torrent Pharma is betting heavily on its flagship diabetes brand Chqornet, a sitagliptin-based tablet positioned as a once-daily DPP-4 inhibitor for adults with type 2 diabetes in India’s fast-growing chronic care market. The prescription oral drug, marketed in strengths including 50 mg and 100 mg sitagliptin, sits at the center of Torrent’s push to expand its share in the domestic anti-diabetic segment, where chronic therapies already contribute a majority of the company’s branded formulations revenue according to its annual disclosures. Torrent’s official product information describes Chqornet as a sitagliptin formulation indicated for glycemic control in type 2 diabetes.

How Chqornet fits into Torrent’s flagship diabetes portfolio

Chqornet is Torrent Pharma’s branded version of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing incretin levels to stimulate insulin release and reduce glucagon, thereby lowering blood glucose in type 2 diabetes patients who still produce some insulin. In India, sitagliptin combinations and monotherapy tablets have become mainstream add-on options to metformin, and Torrent positions Chqornet for physicians managing patients who need tighter control without switching to injectables such as insulin or GLP-1 agonists. While the company does not publish public ex-factory prices for every SKU, Indian trade listings and market trackers place Chqornet among the mid-priced DPP-4 brands, reflecting Torrent’s strategy of combining recognized molecules with relatively affordable chronic treatment packs for long-term adherence. Industry coverage of Torrent’s India strategy points out that chronic therapies like cardiovascular and diabetes brands are core revenue drivers.

From a product strategy perspective, Chqornet complements Torrent’s broader diabetes franchise, which includes fixed-dose combinations pairing sitagliptin with metformin to simplify multi-drug regimens. The company’s India-focused portfolio is heavily skewed toward chronic conditions such as cardiology, diabetology, central nervous system and gastro-intestinal disorders, and management has repeatedly highlighted in investor presentations that chronic therapies generate a large share of branded generic sales and margins. For prescribers, the Chqornet brand offers continuity where Torrent already has a strong presence through cardiac and hypertension drugs, allowing the firm to leverage its existing doctor relationships and distribution network to increase prescription share. In practice, that means Chqornet tablets are primarily dispensed through Indian retail pharmacies and hospital channels on the back of physician prescriptions, rather than via over-the-counter sales or international export programs.

Clinically, sitagliptin-based treatment like Chqornet is normally used alongside diet and exercise, often as an add-on when metformin alone does not provide adequate glycemic control, and sometimes in triple therapy with other oral agents. Like other DPP-4 inhibitors, it is typically valued for a relatively neutral effect on body weight and a lower risk of hypoglycemia compared with certain older diabetes drugs when used without insulin or sulfonylureas, although dosing and suitability always depend on individual patient profiles and renal function. For Torrent, broad clinician familiarity with the sitagliptin class lowers educational barriers and allows the company to focus its promotional resources on brand differentiation, pack sizes and adherence programs rather than on basic mechanism-of-action training. In India’s price-sensitive market, maintaining a consistent, widely available flagship in this category is critical to preserving share against a long list of domestic and multinational competitors selling their own sitagliptin or other DPP-4 brands.

At present, Chqornet is marketed primarily in Torrent Pharma’s home market of India and is not positioned as a US or European export brand, so there is no official US list price or Food and Drug Administration label tied to the Chqornet name. Instead, Indian physicians prescribe the product under Torrent’s domestic marketing authorization, while generic sitagliptin and combinations for Western markets tend to be supplied under different labels or by other manufacturers. The brand’s role as a flagship within Torrent’s chronic portfolio is underscored in company communications that repeatedly stress the group’s reliance on cardiometabolic therapies as a growth pillar, including diabetes medicines alongside cardiac and hypertension drugs. Because type 2 diabetes prevalence in India continues to climb, long-term prescription volumes in this segment are strategically important to Torrent’s formulation business and its efforts to hold or gain share in urban and semi-urban markets where branded generics dominate prescribing behavior.

Within the broader company context, Chqornet sits in a product basket that has helped Torrent Pharma rank among India’s leading chronic-focused pharmaceutical firms, with branded generics in India and Brazil and a separate generics and contract manufacturing presence in markets such as the US. The company is publicly listed in India, and chronic therapies including diabetes care form a meaningful portion of its India formulations revenue, although individual brand sales for Chqornet are not broken out separately in public filings. Shares of Torrent Pharmaceuticals (INE482A01020) are listed on the National Stock Exchange of India and the BSE in Mumbai, where the stock last traded in Indian rupees as part of the benchmark pharmaceutical segment. Exchange data from the National Stock Exchange confirm Torrent’s listing and categorize it within the pharmaceuticals sector.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.